Welcome!

News Feed Item

Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Eli Lilly & Co. Analyst Notes 

On March 31, 2014, Eli Lilly & Co. (Lilly) announced that the U.S. District Court for the Southern District of Indiana has ruled in the Company's favor regarding the vitamin dosage regimen patent for Alimta® (pemetrexed for injection). According to the Company, in the case of Eli Lilly and Company v. Teva Parenteral Medicines Inc., et al., the court ruled the vitamin dosage regimen patent is valid and enforceable. Additionally, the Company stated that the patent provides intellectual property protection for Alimta until 2022. Michael J. Harrington, Senior Vice President and General Counsel for Lilly, remarked, "We are pleased with the District Court's ruling on Alimta's vitamin dosage regimen patent and are confident that the patent is valid and enforceable. The significant scientific research that Lilly performed in support of the vitamin dosage regimen patent deserves intellectual property protection. We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve." The full analyst notes on Eli Lilly & Co. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/LLY/report.pdf

--

UnitedHealth Group, Inc. Analyst Notes 

On March 27, 2014, UnitedHealth Group, Inc. (UnitedHealth Group) announced that the UnitedHealth Group Center for Nursing Advancement (CFNA) reported the formation of an External Nurse Advisory Board (ENAB). According to UnitedHealth, the goal of the ENAB is to inform, create and evolve nursing best practices in order to create strong partnerships across nursing, education and the health care industry influence nursing policy and changes in the national landscape; and further the nursing profession. Commenting on the development, Jeannine Rivet, Executive Vice President, UnitedHealth Group and Executive Sponsor of the CFNA, stated, "The Center for Nursing Advancement (CFNA) was founded in 2008 to prepare nurses for expanding roles and solving the most pressing health care problems of today and tomorrow, tackling the challenges of a health care system in transition and shaping the future of the health care industry. The ENAB was created to further this mission, not only for the more than 24,000 UnitedHealth Group nurse employees in the United States and seven other countries, but for nurses everywhere." The full analyst notes on UnitedHealth Group, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/UNH/report.pdf

--

Valeant Pharmaceuticals International, Inc. Analyst Notes 

On March 25, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) and Actavis plc (Actavis) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). According to the Company, Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013 and under the terms of the agreement with Valeant, Actavis will acquire the rights to Metronidazole 1.3% for up to $57 million in upfront payments, milestone payments and certain guaranteed royalty payments during the first three years of commercialization depending on market conditions. The Company further stated that Actavis will also pay ongoing royalties to Valeant after the first three years of commercialization. The full analyst notes on Valeant Pharmaceuticals International, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/VRX/report.pdf

--

Forest Laboratories Inc. Analyst Notes 

On March 31, 2014, Forest Laboratories Inc. (Forest Laboratories), together with Gedeon Richter Plc., reported positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. According to the Company, the trial consisted of four treatment groups: cariprazine 0.75 mg/day, 1.5 mg/day, 3.0 mg/day, and placebo. Commenting on the results, Marco Taglietti, M.D., Executive Vice President of Drug Development and Research at Forest Laboratories, stated, "We are pleased with the positive results of this study. In addition to previously completed Phase III trials in schizophrenia and bipolar mania, we now have positive Phase IIb studies for cariprazine in both bipolar depression and major depressive disorder. Our goal is to continue developing cariprazine for patients with a broad range of psychiatric conditions." The full analyst notes on Forest Laboratories Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/FRX/report.pdf

--

Zoetis Inc. Analyst Notes 

On March 31, 2014, Zoetis Inc. (Zoetis) announced that it will host a webcast and conference call at 8:30 a.m. EDT on May 6, 2014. According to Zoetis, CEO Juan Ramón Alaix and Executive Vice President and CFO Rick Passov will review Q1 2014 financial results and respond to questions from financial analysts during the call. Additionally, the Company stated that a replay of the webcast will be archived and made available on the same day. The full analyst notes on Zoetis Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/ZTS/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

 

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
SYS-CON Events announced today that MangoApps will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device.
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effi...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, explained how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
“delaPlex Software provides software outsourcing services. We have a hybrid model where we have onshore developers and project managers that we can place anywhere in the U.S. or in Europe,” explained Manish Sachdeva, CEO at delaPlex Software, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
"We've discovered that after shows 80% if leads that people get, 80% of the conversations end up on the show floor, meaning people forget about it, people forget who they talk to, people forget that there are actual business opportunities to be had here so we try to help out and keep the conversations going," explained Jeff Mesnik, Founder and President of ContentMX, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.